Phase 1 Trial of VAS-101 Gel for Improved Curcumin Absorption in Sickle Cell Disease
A clinical trial is underway to evaluate the efficacy of VAS-101, a skin gel containing curcumin, in patients with stable sickle cell disease.
Asset / Drug
Drug and asset intelligence for VAS-101 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.